Improving the information content of categorical clinical trial endpoints

Controlled Clinical Trials

Volumn 23, Issue 5, 2002, Pages 502-514

  Berger, Vance W ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

Binary test; Composite endpoint; Lancaster decomposition; Omnibus test

Indexed keywords

ANTIRETROVIRUS AGENT; CHLORMETHINE; CHLORPROMAZINE; CISPLATIN; DANAPAROID; DEXAMETHASONE; ETANERCEPT; HYPERICUM PERFORATUM EXTRACT; METHOTREXATE; ONDANSETRON; SOTALOL; TALC;

ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DECOMPOSITION; DEPRESSION; DISEASE SEVERITY; ERROR; HEART REINFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL DECISION MAKING; MEDICAL INFORMATION; NAUSEA; PLEURA EFFUSION; RHEUMATOID ARTHRITIS; STATISTICAL ANALYSIS; VOMITING;

BIAS (EPIDEMIOLOGY); CLINICAL TRIALS; DATA COLLECTION; ENDPOINT DETERMINATION; HUMANS; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 0036775214     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-2456(02)00233-7     Document Type: Article

References (38)

1. Sammel M.D., Ryan L.M. Latent variable models with fixed effects. Biometrics. 52:1996;650-663.
2. Permutt T., Berger V.W. Rank tests in ordered 2xk contingency tables. Communications in Statistics, Theory and Methods. 29:2000;989-1003.
3. Sankoh A.J., Huque M.F., Russell H.K., D'Agostino R.B. Global two-group multiple endpoint adjustment methods applied to clinical trials. Drug Info J. 33:1999;119-140.
4. Rosenbaum P.R. Some poset statistics. Ann Stat. 19:1991;1091-1097.
5. Berger V. Pros and cons of permutation tests. Stat Med. 19:2000;1319-1328.
6. Moses L.E., Emerson J.D., Hosseini H. Analyzing data from ordered categories. N Engl J Med. 311:1984;442-448.
7. Emerson J.D., Moses L.E. A note on the Wilcoxon-Mann-Whitney test for 2xk ordered tables. Biometrics. 41:1985;303-309.
8. Rahlfs V.W., Zimmermann H. Scores. ordinal data with few categories - how should they be analyzed? Drug Info J. 27:1993;1227-1240.
9. Senn S. Statistical issues in drug development. 1997;John Wiley and Sons, Chichester.
10. Heyse J.F. Outcome measures in clinical trials. Armitage P., Colton T. The encyclopedia of biostatistics, Vol. 4. 1998;3214-3219 John Wiley and Sons, Chichester.
11. Berger V.W., Permutt T., Ivanova A. The convex hull test for ordered categorical data. Biometrics. 54:1998;1541-1550.
12. CASS Investigators Coronary Artery Surgery Study (CASS). a randomized trial of coronary artery bypass surgery Circulation. 68:1983;939-950.
13. Weinblatt M.E., Kremer J.M., Bankhurst A.D.et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 340:1999;253-259.
14. Felson D.T., Anderson J.J., Lange M.L., Wells G., Lavalley M.P. Should improvement in rhueumatoid arthritis clinical trials be defined as 50% or 70% improvement in core set measures, rather than 20%? Arthritis Rheum. 41:1998;1564-1570.
15. Albers G.W. Choice of endpoints in antiplatelet trials. Neurology. 54:2000;1022-1028.
16. Fisher L.D., Moye L.A. Carvedilol and the food and drug administration approval process. an introduction Control Clin Trials. 20:1999;1-15.
17. Cohn J.N., Fowler M.B., Bristow M.R.et al. Safety and efficacy of carvedilol in severe heart failure. J Card Fail. 3:1997;173-179.
18. Clark W.M., Wissman S., Albers G.W.et al. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke three to five hours after symptom onset. JAMA. 282:1999;2019-2026.
19. TOAST Investigators. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke. JAMA 1998;279:1265-1272.
20. Yancy C.W. Clinical trials of beta-blockers in heart failure. a class review Am J Med. 110:2001;7S-10S.
21. Berger V.W. Comment on Ludbrook and Dudley. American Statistician. 54:2000;85-86.
22. Bertele V., Roncaglioni M.C., Pangrazzi J.et al. Clinical outcome and its predictors in 1560 patients with critical leg ischaemia. Eur J Vasc Endovasc Surg. 18:1999;401-410.
23. Kirkpatrick C.H., Alling D.W. Treatment of chronic oral candidiasis with clotrimazole troches. N Engl J Med. 299:1978;1201-1203.
24. Elwood J.M. Critical appraisal of epidemiological studies and clinical trials. 1998;Oxford University Press, Oxford.
25. Fox S.M., Einhorn L.H., Cox E., Powell N., Abdy A. Ondansetron versus ondansetron, dexamethasone, and chlorpromazine in the prevention of nausea and vomiting associated with multiple-day cisplatin chemotherapy. J Clin Oncol. 11:1993;2391-2395.
26. Fentiman I.S., Rubens R.D., Hayward J.L. Control of pleural effusions in patients with breast cancer. Cancer. 52:1983;737-739.
27. Shelton R.C., Keller M.B., Gelenberg A.et al. Effectiveness of St. John's wort in major depression. JAMA. 285:2001;1978-1986.
28. Staszewski S., Keiser P., Montaner J. Abacavir-lamivudine-zidovudine vs. indinavir-lamivudine-zidovudine in antiretroviral-naïve HIV-infected adults. JAMA. 285:2001;1155-1163.
29. Berger V.W., Ivanova A. Bias of linear rank tests for stochastic order in ordered categorical data. Journal of Statistical Planning and Inference. 107:2002;. in press.
30. Jaeschke R., Singer J., Guyatt G.H. A comparison of seven-point and visual analogue scales. Control Clin Trials. 11:1990;43-51.
31. Maurer W., Commenges D. Choice and analysis of judgement criteria. Capildeo R., Orgogozo J.M. Methods in clinical trials in neurology. 1988;29-55 Macmillan Press, London.
32. Berger V.W., Lunneborg C., Ernst M.D., Levine J.G. Parametric analyses in randomized clinical trials. Journal of Modern Applied Statistical Methods. 1:2002;74-82.
33. Berger VW. Publishing raw categorical data in full. Electronic response to: Infopoints: Publishing Raw Data and Real Time Statistical Analysis on E-Journals. ≪www.bmj.com/cgi/eletters/322/7285/530#EL4≫ 4/12/01.
34. Svensson E. Construction of a single global scale for multi-item assessments of the same variable. Stat Med. 20:2001;3831-3846.
35. Burris H.A., Moore M.J., Andersen J.et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer. a randomized trial J Clin Oncol. 15:1997;2403-2413.
36. Berger V. Admissibility of exact conditional tests of stochastic order. Journal of Statistical Planning and Inference. 66:1998;39-50.
37. Cook D.J., Hébert P.C., Heyland D.K.et al. How to use an article on therapy or prevention. pneumonia prevention using subglottic secretion drainage Crit Care Med. 25:1997;1502-1513.
38. Burls A., Cabello-Lopez J. Research methods in public health. Bradley P., Burls A. Ethics in public and community health. 1999;135-147 Routledge, London.